Celsius Holdings Reports Pro Forma Adjusted EBITDA of $522.3M

By Tamara Parker • Monday, September 22 15:34 • Permanent Link

In the latest financial report, Celsius Holdings, Inc. disclosed its adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) and various adjustments made to the figures. The pro forma adjusted EBITDA for the last twelve months ending June 30, 2025, was reported at $522.3 million.

Compared to the prior period, there are notable changes in the adjustments made to the non-GAAP EBITDA. Stock-based compensation saw an increase from $22.7 million to $318.8 million. Acquisition & reorganization costs also surged from $47.4 million to $54.0 million. Similarly, inventory step-up adjustments rose from $21.7 million to $48.2 million.

Conversely, foreign exchange gains or losses decreased from ($0.6) million to ($1.8) million, while penalties decreased from $10.1 million to $9.9 million. Notably, there was an increase in unrealized synergies from $0 in the prior period to $48.2 million in the current period.

These adjustments provide a more accurate comparison of operating results and offer insights into the impact of various expenses on the company's performance. It's evident that certain expenses, such as stock-based compensation and acquisition costs, have significantly impacted the company's adjusted EBITDA in the current period compared to the prior period. The market has reacted to these announcements by moving the company's shares -5.59% to a price of $51.67. For the full picture, make sure to review Celsius's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.